|
Characteristics
|
Totality, n (%)
|
Median (range)
|
|---|
|
Gender
|
361
| |
|
Male
|
196 (54.3%)
| |
|
Female
|
165 (45.7%)
| |
|
Age
|
361
|
43 (16–76) years
|
|
FAB classification
|
|
M1
|
19 (5.3%)
| |
|
M2
|
193 (53.5%)
| |
|
M4
|
63 (17.5%)
| |
|
M5
|
75 (20.8%)
| |
|
M6
|
6 (1.7%)
| |
|
Undefined
|
5 (1.4%)
| |
|
WBC
|
356 (98.6%)
|
14.7 (0.4–426.0), × 109/L
|
|
LDH
|
341 (94.5%)
|
363 (17–5853), U/L
|
|
BM blast %
|
348 (96.4%)
|
71% (17–99%)
|
|
RBC
|
356 (98.6%)
|
2.19 (0.67–4.98), × 1012/L
|
|
Hemoglobin
|
356 (98.6%)
|
72 (27–149), g/L
|
|
Platelets
|
356 (98.6%)
|
34 (2–546), × 109/L
|
|
Neutrophil
|
356 (98.6%)
|
2.2 (0.0–340.3), × 109/L
|
|
Risk stratifications
|
|
Low risk
|
71 (19.7%)
| |
|
Intermediate risk
|
187 (51.8%)
| |
|
High risk
|
78 (21.6%)
| |
|
Undefined
|
25 (6.9%)
| |
|
FLT3-ITD mutation
|
|
Positive
|
42 (11.6%)
| |
|
Negative
|
294 (81.4%)
| |
|
Unknown
|
25 (6.9%)
| |
|
NPM1 mutation
|
|
Positive
|
67 (18.6%)
| |
|
Negative
|
269 (74.5%)
| |
|
Unknown
|
25 (6.9%)
| |
|
CEBPA mutation
|
|
Positive
|
50 (13.9%)
| |
|
Negative
|
286 (79.2%)
| |
|
Unknown
|
25 (6.9%)
| |
|
Karyotype
|
|
Normal
|
255 (70.6%)
| |
|
Abnormal
|
84 (23.3%)
| |
|
Unknown
|
22 (6.1%)
| |
|
Allo-HCT
|
|
Yes
|
64 (17.7%)
| |
|
No
|
297 (82.3%)
| |
|
CR after two courses of induction therapy
|
|
Yes
|
205 (56.8%)
| |
|
No
|
120 (33.2%)
| |
|
Not evaluated
|
36 (10.0%)
| |
|
Chemotherapy regimens
|
|
MA
|
125 (34.6%)
| |
|
IA
|
86 (23.8%)
| |
|
TA
|
47 (13.0%)
| |
|
DA
|
31 (8.6%)
| |
|
CAG
|
52 (14.4%)
| |
|
Other regimens
|
20 (5.5%)
| |
- FAB French–Britain–American, WBC white blood cell, LDH lactate dehydrogenase, BM bone marrow, RBC red blood cell, Allo-SCT allogeneic hematopoietic stem cell transplantation, CR complete remission, THP pirarubicin, MA Ara-C + mitoxantrone, IA Ara-C + idarubicin, TA Ara-C + THP, DA Ara-C + daunorubicin, CAG Ara-C + aclarubicin + G-CSF
